1st Circ. Revives Investors' Feraheme Risks Class Action
By Daniel Wilson ( February 5, 2013, 3:25 PM EST) -- The First Circuit on Monday revived a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks associated with iron deficiency treatment Feraheme, ruling the investors had made a reasonable claim that AMAG had failed to disclose relevant information on those risks....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.